Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022

Wednesday, February 25, 2015

Bayer HealthCare and Aronora, Inc. today announced its strategic alliance to manufacture Aronora's AB-022 compound for the treatment of cardiovascular diseases. As a tenant of the U.S. CoLaborator, Bayer's life sciences incubator facility based in San Francisco, Aronora will partner with Bayer HealthCare's Global Biologics Development group in Berkeley for the pre-clinical manufacturing of AB-022.

"We have established a close, trusted relationship with Bayer HealthCare," said Andras Gruber, CEO of Aronora.  "We are thrilled to extend our relationship with this agreement. The close proximity of Bayer's research and manufacturing sites to the CoLaborator has made this partnership a natural fit for us. The in-depth drug discovery and manufacturing expertise at Bayer has been valuable for advancing our compound towards the clinic."

"This partnership with Aronora highlights Bayer's unique Bay Area footprint spanning from early stage research through development and manufacturing. We are proud to offer our partners access to Bayer's experts across the entire drug development process," said Chris Haskell, Head of Bayer's U.S. Science Hub. "Our partnering strategy is designed to be flexible, to meet the needs of our collaborators—including start-ups like Aronora. We are excited to advance this collaboration to share our manufacturing expertise and capabilities."

Bayer HealthCare's Bay Area biotechnology presence includes its U.S. Innovation Center in San Francisco and Bayer's Berkeley site, which is a global biologics manufacturing center and functions as the headquarters for its biotechnology product supply organization.

About Aronora, Inc.

Aronora, Inc. is a small translational biotechnology company engaged in the early-stage commercial development of proprietary biologics. Aronora is based in Portland, Oregon, with satellite operations in San Francisco, California. Aronora's products are intended to be used in difficult-to-treat life-threatening diseases, including heart attack, stroke, and severe infection-associated coagulopathy. These conditions often present as true medical emergencies that currently have no or limited causal field treatments. Building on the company's ground-breaking rational approaches to exceptional drug safety, Aronora's product candidates have the potential to become first-in-class medical emergency therapeutics. More information is available at

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG, with annual sales of EUR 18.9 billion (2013), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 56,000 employees (Dec 31, 2013) and is represented in more than 100 countries. More information is available at

About Bayer in the Bay Area

Bayer HealthCare is the third largest biotech employer in the Bay Area and a global leader in the research, development and manufacturing of biotechnology and specialty pharmaceutical therapies that improve human health. Bayer HealthCare's presence on the U.S. West Coast includes a manufacturing facility in Berkeley and its U.S. research hub, the U.S. Innovation Center in San Francisco.


Source :